Australia markets closed

Crescita Therapeutics Inc. (CRRTF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
0.32000.0000 (0.00%)
At close: 02:14PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.3200
Open0.3200
Bid0.0000 x 0
Ask0.0000 x 0
Day's range0.3200 - 0.3200
52-week range0.2500 - 0.5500
Volume1,000
Avg. volume25
Market cap6.275M
Beta (5Y monthly)1.65
PE ratio (TTM)N/A
EPS (TTM)-0.0700
Earnings date09 May 2024 - 13 May 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Business Wire

    Crescita Reports Q4 and Fiscal 2023 Results

    LAVAL, Quebec, March 13, 2024--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2023 ("Q4-2023" and "F2023"). All amounts presented are in thousands of Canadian dollars ("CAD") unless otherwise noted, and in accordance with International Financial Reporting Standards ("IFRS") as issued by

  • Business Wire

    Crescita Reports Third Quarter 2023 Results

    LAVAL, Québec, November 08, 2023--Crescita Therapeutics Inc. (TSX: CTX and OTC US: CRRTF) ("Crescita" or the "Company"), a growth-oriented, innovation-driven Canadian commercial dermatology company, today reported its financial results for the third quarter ended September 30, 2023 ("Q3-2023"). All amounts presented are in thousands of Canadian dollars ("CAD") unless otherwise noted.

  • Business Wire

    Crescita Therapeutics Announces Approval of Normal Course Issuer Bid

    LAVAL, Quebec, August 29, 2023--Crescita Therapeutics Inc. (TSX: CTX) (OTC US: CRRTF) ("Crescita" or the "Company") announced today that the Toronto Stock Exchange (the "TSX") has approved the Company’s proposed normal course issuer bid ("NCIB") to purchase up to a maximum of 1,821,616 common shares ("Common Shares") for cancellation, representing approximately 10% of its public float as of August 18, 2023, as appropriate opportunities arise from time to time. As of August 27, 2023, the Company